Xiaoyan Wang | Immunology Cellular Interactions | Best Paper Award

Published on by Cell Biologist

Ms. Xiaoyan Wang | Immunology Cellular Interactions | Best Paper Award

Ms. Xiaoyan Wang | Fudan University | China

Dr. Xiaoyan Wang is a dedicated cardiologist and postdoctoral fellow at Fudan University with a strong background in both clinical practice and cardiovascular research. With over a decade of academic training and medical experience, she has built expertise in ventricular remodeling, percutaneous coronary interventions, and immune responses in heart diseases. Under the mentorship of esteemed scholars such as Dr. Yunzeng Zou and Academician Yaling Han, she has published extensively in high-impact journals, reflecting her commitment to scientific advancement. Dr. Wang is currently a scholar in Harvard Medical School’s Global Clinical Scholars Research Training program and also serves as a section editor for the AME Clinical Trials Review. She actively contributes to academic communities, notably by organizing the “Excellent Academic Research Communication Club.” Her work bridges translational medicine and clinical application, aiming to improve cardiovascular patient outcomes through innovative, evidence-based approaches.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Outstanding Academic Credentials: Dr. Wang has earned her PhD from the prestigious Fudan University and is currently in the Harvard Medical School’s Global Clinical Scholars Research Training Program, signaling a top-tier academic and global research profile.

  2. Dual Research Strength in Basic and Clinical Sciences: She demonstrates an exceptional ability to bridge molecular mechanisms (e.g., immune pathways, cGAS-STING, miRNAs, circular RNAs) with clinical relevance (e.g., myocardial infarction prognosis, anemia impact in PCI), making her work highly translational.

  3. High-Impact Publications: First-author or co-first-author in peer-reviewed journals such as Signal Transduction and Targeted Therapy, Angiology, and Frontiers in Cardiovascular Medicine, with publications tackling cutting-edge cardiovascular topics.

  4. Collaborative and Interdisciplinary Focus: Contributions across institutions and disciplines—partnering with bioinformaticians, clinicians, and molecular scientists—demonstrate strong collaboration skills.

  5. Recognition & Editorial Role: Multiple awards (CPSF Fellowship, Super Postdoc at Fudan) and an editorial position at AME Clinical Trials Review show leadership and peer acknowledgment.

🛠️ Areas for Improvement:

  1. More First-Author Lead on Recent Papers: Although she holds strong co-first authorships and collaborative contributions, maintaining or increasing sole first-author outputs on impactful papers would further strengthen individual scholarly identity.

  2. Increased International Conference Visibility: While she has presented at JCS, continued or expanded visibility in global cardiovascular congresses (e.g., AHA, ESC, ACC) would enhance recognition.

  3. Grant Leadership: Future grant applications as a principal investigator (rather than team member) could affirm her leadership in project design and execution.

🎓 Education :

Dr. Xiaoyan Wang holds a Ph.D. from Fudan University’s Zhongshan Hospital (2016–2019), where she conducted fundamental research on ventricular remodeling under Dr. Yunzeng Zou’s mentorship, supported by prestigious national fellowships. She earned her Master’s degree from Dalian Medical University (2013–2016), focusing on clinical research in percutaneous coronary intervention, under Academician Yaling Han. Her academic foundation was laid with a Bachelor’s degree in Medicine from Fujian Medical University (2007–2012). Currently, she is advancing her research and clinical skills in the prestigious Global Clinical Scholars Research Training Program at Harvard Medical School (2024–2025), blending in-person and online modules. Her multi-tiered education reflects a deep integration of basic science, translational medicine, and clinical practice in cardiovascular health, equipping her to lead high-impact research and patient care initiatives.

💼 Experience:

Dr. Wang is currently a Postdoctoral Fellow at Fudan University (since 09/2023), working under Prof. Yunzeng Zou. She is also the organizer of the Excellent Academic Research Communication Club, promoting interdisciplinary dialogue. From 07/2022 to 07/2023, she served as a cardiologist at Shanghai Jiaotong University’s Ruijin Hospital, and from 2019 to 2022, as a resident in internal medicine at Zhongshan Hospital. In 2024, she began contributing as a section editor for AME Clinical Trials Review, enhancing the quality and visibility of clinical trial research. Her experience spans clinical cardiology, postdoctoral research, editorial responsibilities, and academic leadership. These roles have solidified her ability to translate scientific knowledge into medical practice, particularly in the cardiovascular field.

🏆 Awards & Honors:

Dr. Wang has received numerous accolades recognizing her academic excellence and research impact. In 2023, she was awarded both the Postdoctoral Fellowship Program of the China Postdoctoral Science Foundation (CPSF) and the prestigious Super Postdoctoral Fellowship of Fudan University, underscoring her leadership in postdoctoral research. Her communication and writing skills were acknowledged with the Third Prize in the 8th “Buchang Cup” Young Physician Essay Contest (2019). She also presented Late Breaking Cohort Studies at the Japanese Circulation Society (JCS) Annual Meeting 2019, reflecting international recognition of her scientific contributions. These honors reflect her potential as a rising leader in cardiovascular medicine and support her suitability for the Best Paper Award.

🔬 Research Focus :

Dr. Wang’s research focuses on cardiovascular disease mechanisms, particularly immune system regulation, ventricular remodeling, and the molecular basis of heart failure. Her Ph.D. and postdoctoral studies have addressed the cGAS-STING pathway, miRNA biomarkers, circular RNAs, and inflammation-related signaling in cardiovascular dysfunction. She has also explored clinical prognostic models, such as CHA2DS2-VASc scoring, and interventions including left atrial appendage occlusion and shock wave therapy for ischemic cardiomyopathy. Her dual interest in basic science and clinical outcomes allows her to design translational research that bridges laboratory findings and therapeutic advancements. With a strong publication record and ongoing involvement in global research training at Harvard Medical School, her work aims to inform precision medicine strategies in cardiology.

📚 Publication Titles Top Notes:

  1. 🧠 The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications

  2. 🔗 The connection of immune response and cGAS-STING pathway in cardiovascular disease

  3. 🐭 Left ventricular response in hypertrophy-to-failure transition: roles of Akt, β-arrestin-2, and CaMKII

  4. 💉 Circulating miRNAs in hypertension: diagnostic value and bioinformatics analysis

  5. 🧪 Galectin-3 inhibition improves endothelial progenitor function via autophagy suppression

  6. 🔄 Circular RNA in cardiovascular disease

📌 Conclusion:

Dr. Xiaoyan Wang is highly suitable for the Research for Best Paper Award. Her profile reflects a rare and valuable integration of basic cardiovascular science and clinical innovation, with high-impact, well-cited publications and ongoing international training. Her trajectory, marked by excellence, discipline, and collaborative leadership, meets and exceeds the criteria for this award.

Tamara Braut | Cancer Cell Biology | Innovative Research Award

Published on by Cell Biologist

Prof. Dr. Tamara Braut | Cancer Cell Biology | Innovative Research Award

Prof. Dr. Tamara Braut | Faculty of Medicine, University of Rijeka/ENT Clinic, Clinical hospital centre Rijeka | Croatia

Professor Tamara Braut, MD, is a renowned Croatian otorhinolaryngologist and Full Professor at the Faculty of Medicine, University of Rijeka. She serves as the Head of the Department of Otorhinolaryngology and Head and Neck Surgery. Her clinical expertise and academic leadership have significantly contributed to advancements in the diagnosis and treatment of head and neck cancers, particularly laryngeal carcinoma. With over two decades of experience, Dr. Braut is widely recognized for her work in molecular oncology, HPV-associated head and neck tumors, and translational medicine. A frequent collaborator on interdisciplinary and international projects, she is committed to personalized medicine and innovative approaches in clinical research. Her impressive portfolio of peer-reviewed publications, including case studies, multicenter analyses, and biomarker-based diagnostics, highlights her dedication to evidence-based practice and academic excellence. Professor Braut’s academic leadership and clinical insight place her among the top contributors in her specialty within Croatia and internationally.

Publication Profile:

Google Scholar

Strengths For Award:

  • Pioneering work in head and neck oncology and molecular diagnostics

  • Significant publication record in high-impact journals

  • Collaborative multicenter research and precision medicine orientation

  • Demonstrated leadership in academic and clinical settings

  • Integration of clinical insights with research innovation

Areas for Improvement:

  • Broaden research beyond oncology to explore ENT-related AI/technology

  • Increase international collaborations and visibility at global conferences

  • Expand into clinical trials for therapeutics in HPV+ cancers

🎓 Education: 

Prof. Tamara Braut received her Doctor of Medicine (MD) degree from the University of Rijeka, Croatia, where she also completed her specialization in Otorhinolaryngology. Her academic path was distinguished by an early interest in oncology, molecular pathology, and surgical innovation. She pursued postgraduate training and research with a focus on laryngeal and head and neck cancers. Throughout her education, she was actively involved in academic research, participating in numerous national and international conferences, which sharpened her analytical and investigative skills. She later obtained her PhD with a focus on molecular markers in squamous cell carcinoma. Over the years, she has pursued continuous professional development in precision medicine, oncology biomarkers, and evidence-based surgical practices. Her academic and clinical training has made her a highly competent physician-scientist, well-versed in both patient care and experimental research.

🧑‍🔬 Experience:

Prof. Tamara Braut has over two decades of experience in clinical and academic medicine. She currently serves as the Head of the Department of Otorhinolaryngology and Head and Neck Surgery at the Faculty of Medicine, University of Rijeka. Her career spans clinical work, academic leadership, surgical practice, and scientific research. She has treated complex cases involving laryngeal and head-neck cancers and has led multidisciplinary teams in oncology care. As an educator, she has supervised medical students, residents, and PhD candidates, many of whom now hold academic and clinical positions. Dr. Braut is a prolific researcher, contributing to over 40 peer-reviewed articles, case studies, and reviews. Her leadership in multicenter studies and her role as a principal investigator in several clinical research projects highlight her competence in collaborative and innovative medical research.

🔬 Research Focus:

Prof. Braut’s research focus lies at the intersection of head and neck oncology, molecular diagnostics, and personalized medicine. She has a keen interest in biomarker discovery, especially in HPV-positive head and neck squamous cell carcinomas, and the role of EGFR signaling pathways in cancer progression. Her work includes translational research linking clinical findings with molecular data to improve prognosis, diagnosis, and treatment strategies. She has also explored the impact of hormonal therapies, gene expression markers like Ki-67 and IMP3, and novel imaging and diagnostic tools. In recent years, she has expanded her interest to gastroesophageal reflux disease and its implications in ENT disorders. Her contributions reflect a consistent commitment to advancing precision medicine, long-term patient follow-up, and multimodal treatment outcomes. She continues to integrate research into clinical practice, thereby fostering innovation and improved patient care in the otorhinolaryngology field.

📚 Publications List Top Notes:

  1. 🧬 Laryngeal SCC shows stronger Nectin-4 vs Nectin-2 expression – CIMB (2025)

  2. 🥗 GERD Management: From PPIs to Diet & Lifestyle – Gastrointest. Disord. (2025)

  3. 🔍 Advances in HPV-Positive Head & Neck Cancer Diagnostics – Biomolecules (2024)

  4. 🧪 Biomarkers in HPV+ Head and Neck SCC: Precision Medicine – Diagnostics (2024)

  5. 💉 Testosterone Therapy in Advanced Head & Neck SCC – Crit. Rev. Oncol. Hematol. (2023)

  6. 🏥 Long-Term Care in Laryngeal Cancer: Multicenter Analysis – J Pers. Med (2023)

  7. 📊 5-Year Clinical Course in Laryngeal Tumors – Acta Clin. Croatica (2022)

  8. 🧫 Renal Cell Carcinoma Metastasis to Larynx: Rare Case – Medicina Flum (2021)

  9. 🧠 Posttraumatic Vernet Syndrome without Fracture: Case Study – Medicine (2021)

  10. ⚛️ Nuclear EGFR Expression = Poor Survival in Laryngeal Ca – AIMM (2021)

Conclusion:

Prof. Tamara Braut is highly deserving of the Innovative Research Award. Her work showcases originality, clinical relevance, and scientific depth. With a robust academic and clinical foundation, she continues to push the boundaries in ENT oncology and diagnostics.

 

An Dai Tran | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Mr. An Dai Tran | Immunology Cellular Interactions | Best Researcher Award

Mr. An Dai Tran, Walailak University, Vietnam

Dr. An Dai Tran is a dedicated medical doctor and emerging public health researcher from Vietnam, currently pursuing a Master’s degree at Walailak University, Thailand. He works at the CDC Dong Thap, focusing on vaccination programs and infectious disease control, including dengue fever, COVID-19, and measles. With several years of hands-on experience in clinical trials and epidemiological research, Dr. Tran has made significant contributions to community health. His published work on vaccination adherence among minority groups in Vietnam has had real-world impact on public health campaigns. Additionally, he has co-developed innovative tools for behavioral science and contributed to machine learning applications in mental health. Collaborating with global institutions such as the University of Queensland and the Pasteur Institute, Dr. Tran’s work reflects a commitment to translational research, public health equity, and data-driven health interventions. His profile is marked by scientific rigor, international collaboration, and service to underserved populations.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Interdisciplinary Research Excellence
    Dr. Tran’s research spans infectious diseases, vaccination behavior, and digital mental health—demonstrating versatility and innovation in addressing modern public health challenges.

  2. Practical and Policy-Relevant Impact
    His work on vaccination adherence in minority communities has real-world implications for national health policy and outreach programs, especially in underserved populations.

  3. Strong Clinical Trial Experience
    He has held critical roles in major vaccine trials (COVID-19 and hand-foot-mouth disease), showing competence in trial design, blinding, and coordination—essential for translational health research.

  4. Collaborative Global Network
    Dr. Tran has established collaborations with renowned institutions such as the University of Queensland and the Pasteur Institute, boosting the credibility and scalability of his research.

  5. Innovation in Mental Health Analytics
    His application of AI and machine learning to post-COVID mental health challenges shows forward-thinking research methodology with future potential.

  6. Published and Cited
    With publications in peer-reviewed journals like Jornal de Pediatria and Journal of Human, Earth, and Future, and a growing citation index, he is building a solid academic foundation.

🛠️ Areas for Improvement:

  1. Broader Indexing and Citations
    While promising, most of his current publications are in emerging or interdisciplinary journals. Publishing in higher-impact, SCI-indexed journals could enhance academic visibility.

  2. Editorial and Peer Review Roles
    Taking on editorial appointments or peer-review duties would strengthen his professional profile and leadership in research.

  3. Mentorship and Teaching Contribution
    Engaging in formal mentorship or academic teaching roles would reflect his potential as a knowledge disseminator and academic influencer.

  4. Expanded Public Health Policy Impact
    Future work that integrates direct contributions to policy development or national programs would further validate his applied research strengths.

🎓 Education:

Dr. An Dai Tran holds a medical degree and is currently completing a Master’s in Public Health at the School of Public Health, Walailak University, Thailand. He was awarded a full scholarship for his postgraduate studies in recognition of his academic excellence and commitment to public health. His education bridges clinical medicine with population-level health sciences, equipping him with multidisciplinary expertise to tackle emerging global health challenges. At Walailak University, Dr. Tran has deepened his knowledge in epidemiology, biostatistics, global health policy, and digital health technologies. His academic training is complemented by a strong foundation in research methodology and ethics, allowing him to conduct high-impact studies and clinical trials. His exposure to both theoretical and practical facets of public health, along with mentorship from international experts, positions him as a future leader in healthcare innovation, with special focus on vaccine-preventable diseases and mental health research in Southeast Asia.

💼 Professional Experience:

Dr. Tran brings valuable on-ground experience through his work at the CDC Dong Thap in Vietnam, where he has led and supported various national vaccination campaigns and infectious disease monitoring systems. He has been actively involved in both the operational and research aspects of public health interventions. His clinical trial roles include coordinating blinded and double-blinded studies on COVID-19 and hand-foot-mouth vaccines. Notably, he served as a research coordinator in large-scale, placebo-controlled trials with rigorous ethical and methodological frameworks. His consultancy record includes four projects in collaboration with governmental and academic institutions, such as the University of Queensland (E-Dengue Project) and the Pasteur Institute (Vietnam-based vaccine research). Dr. Tran’s experience spans public health research, disease surveillance, behavioral analysis, and machine learning for mental health prediction. His combined roles as physician, coordinator, and academic researcher highlight his versatility, responsibility, and drive for impactful health innovations that reach marginalized communities.

🧠 Research Focus:

Dr. Tran’s research lies at the intersection of infectious diseases, vaccination behavior, and digital mental health. His primary interest is understanding the behavioral and sociocultural factors affecting vaccine uptake, particularly among ethnic minority populations. His first-author publication on this topic has already contributed to improved regional strategies for vaccine delivery. Expanding into digital health, Dr. Tran has co-developed psychological assessment tools and applied machine learning to detect mental health issues in post-COVID patients. His work in computational psychiatry includes Reddit-based community sentiment analysis and comparative modeling for long COVID mental health prediction. By merging AI with public health, he aims to enhance early detection and intervention systems. His approach reflects a holistic vision—bridging clinical practice, community outreach, and technology—with a commitment to healthcare equity. Dr. Tran’s research is not only academically sound but also practically applicable, aligning with Sustainable Development Goals (SDGs) for health and well-being.

📚 Publications Top Notes:

  1. 🧬 Parental predictors of childhood vaccination adherence in border areas of Southern Vietnam – Jornal de Pediatria.

  2. 🏃‍♂️ Initial Construction of the Exercise Maintenance Motivation Scale: A Mixed Method Study – Journal of Human, Earth, and Future.

  3. 🤖 An Analysis of Machine Learning for Detecting Depression, Anxiety, and Stress of Recovered COVID-19 Patients – Journal of Human, Earth, and Future.

  4. 🧠 Exploring Mental Stress Expressions in Online Communities: A Subreddit Analysis – Journal of Human, Earth, and Future.

  5. 🧪 Mental health and long COVID status prediction among recovered COVID-19 patients: A comparison of machine learning methods – Journal of Human, Earth, and Future.

🧾 Conclusion:

Dr. An Dai Tran is a highly promising early-career researcher whose interdisciplinary work in public health is both scientifically rigorous and socially impactful. His blend of clinical trial expertise, digital health innovation, and public health behavior research makes him an ideal candidate for the Best Researcher Award. While there is room to grow in areas like journal prestige and academic leadership, his current trajectory, achievements, and commitment to health equity clearly demonstrate award-worthy excellence.

Drosos Kourounis | Microbial Cell Biology | Best Researcher Award

Published on by Cell Biologist

Mr. Drosos Kourounis | Microbial Cell Biology | Best Researcher Award

Mr. Drosos Kourounis | Hellenic Pasteur Institute| Greece

Drosos Kourounis is a seasoned biomedical scientist based at the Hellenic Pasteur Institute, Greece. With a strong foundation in molecular biology, his career has spanned from research on parasitic protozoa to developing air purification technologies for public health. His journey began with a BSc and MSc in Biology from the University of Athens, focusing on Leishmania molecular mechanisms. He progressively transitioned into applied research and pharmaceutical quality control, currently serving as the QA/QC Manager at the Hellenic Pasteur Institute. Alongside his scientific duties, he has actively participated in several national seminars and certifications in ISO standards and laboratory quality systems. His contributions to publications, including work on UV-C air disinfection and pathogen bioaerosols, show his commitment to translational science and public health safety. Kourounis’s multidisciplinary skills, research impact, and quality-driven mindset make him a standout figure in the field of biomedical research.

Publication Profile:

Ocrid

✅ Strengths for the Award:

  1. Diverse Research Portfolio: Dr. Kourounis combines basic molecular biology research (e.g., Leishmania donovani protein characterization) with applied public health innovations, such as UVC air filtration devices.

  2. Peer-Reviewed Publications: Multiple first- and co-author publications in reputable journals like International Journal of Molecular Sciences and Clinical Research and Reviews highlight his consistent research productivity.

  3. Quality & Regulatory Expertise: His role as QA/QC Manager and extensive ISO training show strong competence in scientific quality assurance, a rare but highly valuable skill in biomedical research.

  4. Public Health Impact: His work on airborne microbial bioaerosols reduction is highly relevant to healthcare, particularly in post-pandemic times.

  5. Academic Excellence: Achieved a 10/10 thesis grade for MSc research and has shown continued academic engagement and scientific rigor.

🛠️ Areas for Improvement:

  1. More International Collaborations: While his current network is strong locally, expanding his collaborations globally would increase visibility and cross-disciplinary impact.

  2. Greater Research Specialization: A more narrowly defined focus could strengthen academic identity and make his profile stand out further among specialized researchers.

  3. Funding and Grants: No mention of securing independent grants or fellowships, which are key indicators of research independence and innovation leadership.

🎓 Education:

Drosos Kourounis holds both a Bachelor of Science (2013) and Master of Science (2017) in Biology from the University of Athens, Greece. His MSc focused on molecular parasitology, specifically the cloning and characterization of a secreted nexin-like protein from Leishmania donovani, which earned him a perfect thesis score (10/10). Complementing his formal education, Kourounis has pursued multiple professional certifications in laboratory quality systems, including ISO 17025 and ISO/IEC 17025 accreditation seminars, conducted by institutions like TUV HELLAS and HellasLab. In 2021, he also completed certified training in laboratory animal science at the Hellenic Pasteur Institute, showing his commitment to ethical and regulatory compliance in biomedical research. His training portfolio demonstrates a keen interest in continuous education and the application of scientific standards in both academic and industrial environments. His educational journey reflects a balance between foundational science and regulatory excellence.

💼 Experience:

Drosos Kourounis has over 7 years of cumulative experience in biomedical research and quality control. He is currently the Quality Assurance and Quality Control Manager at the Hellenic Pasteur Institute (since January 2023), where he oversees pharmaceutical QC processes. Previously, he served as Senior QC Analyst (2022) and QC Analyst (2019–2021) at the same institution. His earlier roles include Scientific Collaborator at MEGALAB S.A. and Research Assistant at the Intracellular Parasitism group in the Hellenic Pasteur Institute. During his research tenure, he contributed to molecular studies on Leishmania donovani and the development of innovative air disinfection systems. He is recognized for his dual role as a scientist and regulatory professional, combining rigorous lab work with compliance to ISO standards. His professional trajectory showcases a steady progression toward leadership in quality control, along with consistent scientific contributions to public health and infectious disease research.

🔬 Research Focus:

Drosos Kourounis’s research lies at the intersection of molecular parasitology, bioaerosol control, and public health technology. His academic work began with the cloning and analysis of Leishmania donovani proteins, contributing to the understanding of host-parasite interactions. Transitioning from pure biology, his focus expanded to the development of innovative air disinfection technologies, including UV-C integrated filtration systems aimed at mitigating microbial exposure in clinical and public environments. This shift highlights a commitment to translational research that addresses real-world problems, such as hospital-acquired infections and airborne pathogen control. His contributions are evident in publications across molecular sciences and applied electromagnetics. Moreover, he incorporates quality assurance principles into his scientific work, ensuring research reproducibility and compliance with international standards.

📚 Publication Top Notes: 

  • 🧬 Cloning and molecular characterization of the secreted nexin-like protein LdPIBPnex, from the protozoon Leishmania donovani

  • 🌬️ Substantial Reduction of Airborne Microbial Bioaerosols by Using a Novel Combination of Air Filtration and UV Irradiation Technology in Areas of Public Interest

  • 🧫 Characterization of the First Secreted Sorting Nexin Identified in the Leishmania Protists

  • 🏥 A Study on the Reduction of Airborne Microbial Bioaerosols at Indoor Air of Hospital’s Intensive Care Unit by Using Novel Air Filtration and UV Irradiation Technology

  • 😷 Design and Analysis of a Protecting Breathing Device (VITER) Disinfecting Air with an Integrated UVC Radiation Mechanism

 

🧾 Conclusion:

Dr. Drosos Kourounis demonstrates exceptional dedication to biomedical research, quality assurance, and innovation in public health safety. His dual focus on molecular parasitology and technological solutions for microbial air control showcases both scientific depth and societal impact. With a growing publication record and leadership role in a premier research institute, he is well-positioned for recognition. Enhancing global visibility and grant acquisition could elevate his profile further. Overall, he is highly suitable and deserving of serious consideration for the Best Researcher Award.

Gökçe Karaotmarlı Güven | Cancer Cell Biology | Best Research Article Award

Published on by Cell Biologist

Mrs. Gökçe Karaotmarlı Güven | Cancer Cell Biology | Best Research Article Award

Mrs. Gökçe Karaotmarlı Güven | Biruni University, Faculty of Pharmacy | Turkey

Gökçe Karaotmarlı Güven, born on July 22, 1996, is a dynamic and passionate Research Assistant with a strong academic foundation in pharmaceutical sciences. She earned her Bachelor’s degree from Biruni University, Faculty of Pharmacy in 2020, and is currently pursuing her Ph.D. in Pharmaceutical Technology at Health Sciences University, where she is deeply involved in cutting-edge nanomedicine research. Her expertise lies in carbon quantum dots, drug delivery systems, and bio-nanotechnology. Gökçe has collaborated on innovative research projects and has contributed significantly to the scientific community through high-impact publications and patent filings. Her interdisciplinary research combines pharmaceutical technology, nanoscience, and biotechnology, aiming to advance targeted drug delivery for diseases like cancer. She is recognized for her analytical mindset, scientific curiosity, and collaborative spirit, which fuel her aspiration to become a leading figure in pharmaceutical nanotechnology. Gökçe continues to explore novel therapeutic technologies to address some of the most pressing challenges in modern medicine.

orcid

✅ Strengths for the Award:

  1. Innovative Research:
    Gökçe has demonstrated a clear focus on high-impact, novel research—especially with her work on boron-doped carbon quantum dots for targeted drug delivery and cancer therapy. Her work represents a pioneering intersection of nanotechnology and pharmaceutical sciences.

  2. High-Quality Publications:
    She has published in internationally respected journals such as Pharmaceuticals, Applied Sciences, and Journal of Research in Pharmacy. The topics she covers—quantum drug development, phytochemical-based wound therapies, and ocular drug delivery—are timely and significant to global health.

  3. Patent Contributions:
    With three patent applications (2024–2025), her research is not only academic but also translational and innovation-driven, showing real-world applicability—a vital criterion for research excellence awards.

  4. Collaborative and Interdisciplinary Work:
    Gökçe has worked with both national and international teams, indicating strong teamwork, adaptability, and leadership in multidisciplinary settings.

🔄 Areas for Improvement:

  1. Broader Publication Indexing:
    Although her work is high quality, more publications in top-tier Q1 journals indexed by PubMed/Scopus/Web of Science would further validate her research’s global impact and improve her visibility.

  2. Post-Doctoral Research Exposure:
    Expanding her research experience internationally through postdoctoral fellowships or collaborations abroad could enhance the depth of her academic profile and increase her competitiveness for global-level research awards.

  3. Greater Conference Participation:
    Active presentation in international conferences, symposiums, or research summits would broaden her academic reach and help disseminate her innovations to a larger audience.

🎓 Education:

Gökçe Karaotmarlı Güven’s educational background reflects her commitment to pharmaceutical sciences and innovation. She obtained her Bachelor’s degree from the Faculty of Pharmacy at Biruni University in 2020, where she developed a solid understanding of pharmaceutical chemistry and drug formulation. Currently, she is pursuing a Ph.D. in Pharmaceutical Technology at the Health Sciences University, Hamidiye Faculty of Pharmacy. Her doctoral research is focused on the synthesis, biodistribution, and pharmacokinetics of boron-doped carbon quantum dots—highly advanced nanomaterials with potential applications in drug delivery and cancer therapy. Under the mentorship of Prof. Dr. Neslihan Üstündağ Okur and co-advisor Prof. Dr. İsmail Tuncer Değim, she is conducting high-level research that blends nanotechnology with targeted therapeutic systems. Her academic training is complemented by active involvement in laboratory-based innovation and scholarly writing, making her well-prepared for an impactful career in both academia and the pharmaceutical industry.

💼 Experience:

Gökçe Karaotmarlı Güven is currently working as a Research Assistant at Health Sciences University, where she contributes to numerous multidisciplinary projects in the field of pharmaceutical nanotechnology. Her professional journey began with laboratory internships and academic projects during her undergraduate years, focusing on drug formulation and ocular drug delivery systems. During her Ph.D., she has played a pivotal role in designing and characterizing nanocarriers for targeted drug delivery, particularly in cancer treatment and wound healing. Her hands-on experience includes formulation science, analytical instrumentation, preclinical biodistribution studies, and in vitro pharmacokinetics. Gökçe has been involved in patentable inventions and has co-authored multiple high-impact journal articles in international journals. Her collaborations span across Turkish and international institutions, showcasing her ability to work in team-based research environments. Her strengths lie in research design, scientific communication, and a deep understanding of advanced drug delivery systems, making her an asset to any pharmaceutical research team.

🔬 Research Focus:

Gökçe Karaotmarlı Güven’s research centers on the intersection of nanotechnology and pharmaceutical sciences, particularly in the development of carbon quantum dots (CQDs) for targeted drug delivery. Her doctoral thesis involves the preparation, biodistribution, and pharmacokinetic evaluation of boron-doped carbon quantum dots and composite carbon quantum dots, aimed at enhancing drug delivery efficiency in cancer treatment. Her interests extend to quantum drug technologies, ocular drug delivery systems, and hydrogel formulations containing bioactive molecules. Through her collaborative research, she explores the role of nanoformulations in wound healing, antimicrobial applications, and personalized medicine. Gökçe is particularly passionate about applying nanotechnology to solve real-world therapeutic challenges, especially in cancer and ophthalmic care. Her work is informed by a multidisciplinary approach, blending pharmaceutical chemistry, nanoscience, and biotechnology. Her research is innovative, patentable, and addresses unmet needs in the current pharmaceutical landscape, positioning her as a rising scholar in next-generation drug delivery systems.

📚 Publications Top Notes:

  1. 🧬 Quantum Drugs (Q-Drugs): A New Discovery and Taboo Breaking Approach; Producing Carbon Quantum Dots from Drug Molecules – Pharmaceuticals, 2025-05-22

  2. 🌿 Nanoformulations Loaded with Phytochemicals for Combating Wound Infections and Promoting Wound Healing – Applied Sciences, 2025-05-12

  3. 👁️ In situ gels loaded with naringin as ocular drug delivery carriers; development and preliminary characterization – Journal of Research in Pharmacy, 2024

  4. 💧 Preparation and characterization of carbopol based hydrogels containing dexpanthenol – Ankara Universitesi Eczacilik Fakultesi Dergisi, 2023-06-12

📝 Conclusion:

Gökçe Karaotmarlı Güven stands out as a highly promising young researcher whose work is innovative, scientifically sound, and application-focused. Her contributions to the development of novel drug delivery systems, particularly through carbon quantum dots and nanomedicine strategies, mark her as a deserving candidate for the Best Research Article Award.

Her work aligns with the values such awards seek to recognize: originality, relevance, translational impact, and collaborative strength. With continued growth in international exposure and expanded publication reach, she will not only be a worthy recipient now but also an influential leader in pharmaceutical nanotechnology in the future.

Eunhee Lee | Neuronal Cell Biology | Best Research Article Award

Published on by Cell Biologist

Dr. Eunhee Lee | Neuronal Cell Biology | Best Research Article Award

Dr. Eunhee Lee, Daegu Gyeongbuk Medical Innovation Foundation, K-MEDI hub, South Korea

Dr. Eun-Hee Lee, Ph.D., is a distinguished biomedical researcher with expertise in therapeutic ultrasound and neurobiology. Currently serving as Senior Researcher and Head of the Advanced Technology Department at the Medical Device Development Center, DGMIF, South Korea, she has consistently contributed to the advancement of focused ultrasound applications in neurological disorders. With over a decade of research experience spanning government institutions and clinical collaborations, Dr. Lee has published extensively in peer-reviewed journals on brain delivery mechanisms, neuroinflammation, and neurodegeneration. Her pioneering studies have deepened our understanding of the blood-brain barrier and the therapeutic potential of ultrasound. Her work stands at the forefront of translational neuroscience, aiming to enhance drug delivery and brain repair mechanisms. Dr. Lee’s dedication to impactful and clinically relevant research makes her a strong contender for the Best Research Article Award.

Publication Profile: 

Scopus

✅ Strengths for the Award

  1. Innovative Research Focus:
    Dr. Lee’s work on focused ultrasound (FUS)-mediated blood-brain barrier (BBB) disruption is at the cutting edge of neurotherapeutics and non-invasive brain drug delivery. Her investigations hold promise for treating neurodegenerative disorders like Alzheimer’s disease and traumatic brain injuries.

  2. Extensive Peer-Reviewed Publications:
    With over 15 high-quality, peer-reviewed articles published from 2019 to 2024 in reputable journals like Scientific Reports, Frontiers in Neuroscience, and Biomedicines, her research output reflects consistent and impactful contributions.

  3. Interdisciplinary Approach:
    Her integration of biomedical engineering, imaging, and neurobiology enhances the translational value of her findings. Numerical modeling and simulation studies further strengthen the clinical feasibility of her techniques.

  4. Clinical and Preclinical Impact:
    Dr. Lee’s work bridges preclinical models (rats, skull simulations) with potential human applications, offering real translational pathways for drug delivery across the BBB.

  5. Leadership and Collaboration:
    As the Head of the Advanced Technology Department at DGMIF, she demonstrates leadership in medical innovation and fosters collaboration between academia, hospitals, and research institutes.

⚠️ Areas for Improvement

  1. Greater International Collaboration:
    While her work is deeply embedded in Korean institutions, expanding partnerships internationally could amplify her research reach and global influence.

  2. Clinical Trial Transition:
    Much of her published work is preclinical. Advancing to clinical trials or human pilot studies would significantly increase the translational impact of her findings.

  3. Public Engagement and Visibility:
    Enhanced visibility through global neuroscience or biomedical engineering conferences could further validate and showcase her research excellence.

🎓 Education:

Dr. Eun-Hee Lee received all her academic training from Chonnam National University, Kwangju, South Korea. She earned her Ph.D. (2007–2010) and M.S. (2005–2007) in Biological Sciences and Technology, gaining extensive knowledge in cellular and molecular biology. Her B.S. in Genetic Engineering (2001–2005) laid the groundwork for her interest in biomedical innovations and neurogenetics. During her graduate and doctoral studies, she focused on cellular pathways and gene expression relevant to neurodegenerative diseases and molecular interventions. Her academic journey shaped her multidisciplinary perspective, merging genetics, bioengineering, and neurobiology. These foundations have enabled her to pursue cutting-edge research on the blood-brain barrier, drug delivery systems, and brain stimulation. Dr. Lee’s strong academic background provides her with the theoretical and technical expertise essential for high-impact research.

🧪 Experience:

Dr. Eun-Hee Lee has more than 14 years of progressive research experience. Since 2017, she has led the Advanced Technology Department at DGMIF, where she develops novel medical devices using therapeutic ultrasound. Prior to this, she worked as a Research Scientist at the Korea Atomic Energy Institute’s Advanced Radiation Technology Institute (2015–2017), where she explored radiation-mediated biological responses. Between 2013 and 2015, she contributed to TB and molecular microbiology research at the Korean Institute of Tuberculosis. Her postdoctoral fellowship (2011–2012) at the NIH’s Division of HIV/AIDS and Tumor Viruses expanded her expertise into virology and immunopathology. Dr. Lee’s multidisciplinary roles across leading institutions demonstrate her adaptability, leadership, and commitment to translational science. Her professional trajectory shows strong contributions to national research priorities in healthcare and medical technology.

🔬 Research Focus:

Dr. Eun-Hee Lee’s research centers on focused ultrasound (FUS) as a non-invasive modality for drug delivery and neural repair. Her work explores ultrasound-mediated blood-brain barrier (BBB) disruption to enhance targeted therapeutic access to the brain. She also investigates ultrasound stimulation’s effects on neurogenesis, neuroinflammation, and neuroprotection in various neurological models including Alzheimer’s disease and spinal cord injury. Another significant area of focus includes numerical modeling of skull structures to improve the precision of transcranial FUS applications. Through collaborations with clinicians and physicists, Dr. Lee has produced evidence-based methodologies for safer, more effective BBB modulation. Her integrative approach, combining bioengineering, neuroimmunology, and computational simulation, is impactful in the field of therapeutic neuromodulation and has implications for treating neurodegenerative and cerebrovascular disorders.

📚 Publications Top Notes: 

  • 🧠 Numerical Investigation of Layered Homogeneous Skull Model for Simulations of Transcranial Focused Ultrasound (2024)

  • 🔥 The New Insight into the Inflammatory Response Following Focused Ultrasound-Mediated Blood-Brain Barrier Disruption (2022)

  • 🧪 Methylene Blue Delivery via Focused Ultrasound Reduces Neural Damage and Amyloid-Beta by AQP-4 Upregulation (2022)

  • 🐀 Novel Animal Model of Spontaneous Cerebral Petechial Hemorrhage Using Focused Ultrasound in Rats (2022)

  • ♻️ Ultrasound Stimulation Improves Inflammation Resolution and Functional Recovery After Spinal Cord Injury (2022)

  • 🚑 Relationship Between Treatment Types and BBB Disruption in Acute Ischemic Stroke: Two Case Reports (2022)

  • 🧲 Effects of Transducer Displacement on Focused Ultrasound in the Rat Brain (2022)

  • 📉 BBB Disruption After Syncope: A DCE-MRI Case Report (2021)

  • 🧪 Verification of BBB Disruption Using Rat Model with Human Skull (2021)

  • 💧 Localized Water Molecule Transport Modulation Post-FUS BBB Disruption (2021)

  • 🚨 DCE-MRI for Evaluating BBB Disruption in Traumatic Brain Injury: Review (2021)

  • 🧬 TREM2 Promotes Natural Killer Cell Development in pNK Cells (2021)

  • 🌿 Gintonin Enhances Donepezil Brain Delivery via LPA and VEGF Receptors (2021)

  • 🔄 Cyclophilin A is a Ligand for TREM2 in Myeloid Cells (2021)

  • 🧠 Local Differences in BBB Permeability Induced by Focused Ultrasound (2020)

  • 💉 Advanced FUS Protocol Improves Doxorubicin Delivery in Rat Brain (2019)

  • 🔄 FUS-Induced Diminished P-glycoprotein via JNK Pathway in Cerebral Vessels (2019)

🧾 Conclusion:

Dr. Eun-Hee Lee is a highly suitable candidate for the Best Research Article Award. Her work is scientifically rigorous, clinically relevant, and methodologically innovative. The focus on ultrasound-mediated drug delivery through the BBB is a transformative area in neuroscience and drug delivery technology. Her comprehensive research output, leadership, and translational potential strongly position her among top contenders for recognition. Encouraging clinical application and broader dissemination will only enhance the already substantial value of her contributions.

Naoki Harada | Molecular Mechanisms Signaling | Best Researcher Award

Published on by Cell Biologist

Dr. Naoki Harada | Molecular Mechanisms Signaling | Best Researcher Award

Dr. Naoki Harada, Osaka Metropolitan University, Japan

Naoki Harada is an Associate Professor at Osaka Metropolitan University, Japan, with extensive expertise in molecular biology, biochemistry, endocrinology, and nutrition. He earned his Ph.D. in Life Sciences from Osaka Prefecture University in 2007. Over the past two decades, Harada has made significant contributions to understanding the physiological and biochemical mechanisms underpinning metabolic diseases, particularly type 2 diabetes. His research, characterized by high citation impact (H-index of 25), centers on pancreatic β-cell function and metabolic regulation. He has published 77 peer-reviewed articles and holds a patent related to therapeutic interventions. Harada has collaborated with leading scientists like Professors Hiroshi Inui and Ryoichi Yamaji, strengthening his academic footprint in both national and international circles. A member of multiple scientific societies, Harada continues to influence the field through impactful research, industry collaboration, and educational leadership.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Consistent Research Output

    • 77 peer-reviewed publications in reputable journals (SCI, Scopus).

    • Recent high-impact studies published in Journal of Biological Chemistry, Scientific Reports, and FASEB BioAdvances.

    • Active research profile with an H-index of 25 and over 1,785 citations.

  2. Innovative Scientific Contributions

    • Identified REDD2 as a novel therapeutic target for type 2 diabetes—bridging basic research with translational medicine.

    • Works across disciplines such as molecular biology, endocrinology, and nutritional biochemistry.

  3. Project Leadership & Industry Engagement

    • Led or participated in 14 major research projects.

    • 5 consultancy/industry-based projects, reflecting application-oriented research.

  4. Academic and Collaborative Network

    • Strong academic collaborations with Professors Hiroshi Inui and Ryoichi Yamaji.

    • Member of prestigious scientific societies (e.g., Japanese Biochemical Society, Japan Society of Nutrition and Food Science).

  5. Scientific Versatility

    • Contributions span fundamental mechanisms (e.g., oxidative stress, insulin signaling) to dietary interventions (e.g., mogrol, oleamide).

    • Demonstrates ability to bridge molecular insights with systemic physiological outcomes.

⚙️ Areas for Improvement:

  1. International Visibility and Engagement

    • Expanding participation in international conferences and editorial boards could elevate his global scientific standing.

    • Pursuing cross-border collaborations would further enrich the translational value of his work.

  2. Commercialization and Patent Activity

    • While one patent is noted, increased focus on intellectual property development and biomedical commercialization could further validate his applied research strength.

  3. Outreach and Communication

    • More active public science communication (e.g., webinars, policy advocacy, media coverage) would amplify the societal impact of his research.

🎓 Education:

Naoki Harada received his Ph.D. in Life Sciences from Osaka Prefecture University, Osaka, Japan, in September 2007. His doctoral studies laid the foundation for his interdisciplinary research in molecular biology, biochemistry, and endocrinology. Harada’s academic path was driven by a keen interest in the cellular and molecular mechanisms underlying metabolic regulation, particularly in relation to glucose homeostasis and pancreatic function. His education provided him with a solid grounding in experimental techniques, critical thinking, and scientific communication, which have become hallmarks of his later work. The institution, known for excellence in biosciences, enabled Harada to cultivate a strong research acumen. His academic training was complemented by exposure to applied research, linking basic science with clinical and nutritional applications—an approach that he has continued to emphasize throughout his career. His strong educational background plays a pivotal role in his current research endeavors and professional development.

💼 Experience:

Dr. Naoki Harada began his academic career in 2008 as an Assistant Professor at the Graduate School of Life and Environmental Sciences, Osaka Prefecture University. He was promoted to Lecturer in 2015, and subsequently to Associate Professor in 2019. Since 2022, he has served as Associate Professor at the Graduate School of Agriculture, Osaka Metropolitan University. Harada has consistently combined teaching with intensive research, mentoring graduate students while advancing his lab’s focus on metabolic diseases and endocrine physiology. His experience includes leading 14 research projects, consulting on 5 industry-linked nutrition initiatives, and co-authoring over 75 scientific papers. His experience reflects a blend of academic leadership, scientific innovation, and multidisciplinary collaboration. Notably, Harada’s role in identifying REDD2 as a therapeutic target exemplifies his contribution to translational science. He maintains strong academic partnerships and actively contributes to several professional societies, making him a respected figure in Japan’s scientific community.

🔬 Research Focus:

Naoki Harada’s research is at the intersection of molecular biology, endocrinology, and nutrition science, with a particular focus on pancreatic β-cell physiology and glucose metabolism. He investigates how oxidative stress, hormonal signals, and metabolic regulators influence insulin secretion and β-cell viability. One of his pivotal contributions is identifying the REDD2 gene as a negative regulator of β-cell function, offering novel therapeutic targets for type 2 diabetes mellitus. His studies also explore nutrient-sensing pathways, G-protein-coupled receptors, and hormonal modulation of energy metabolism. Harada’s recent work delves into the effects of dietary compounds like mogrol and oleamide on metabolic health, linking molecular mechanisms to real-world dietary interventions. His ability to bridge bench science with clinical and nutritional applications sets his research apart. Through collaborations with leading experts and high-impact publications, Harada continues to advance knowledge in the prevention and treatment of metabolic disorders.

📚 Publications Top Notes:

  • 🧬 REDD2 confers pancreatic β-cell dysfunction in high-fat diet-fed mice – Journal of Biological Chemistry, 2025

  • 🦷 Androgens suppress ST3GAL1/4, modulating mucin glycosylation and microbiota in mice – Bioscience, Biotechnology, and Biochemistry, 2025

  • 🍟 CRTC1 in MC4R cells regulates dietary fat intake – FASEB BioAdvances, 2024

  • 💉 Insulin reduces ER stress-induced apoptosis in INS-1 β-cells – Physiological Reports, 2024

  • 🍬 Mogrol activates GPBAR1 and insulin secretion, alleviates hyperglycemia – Scientific Reports, 2024

  • 🔥 Androgen receptor suppresses β-adrenoceptor-mediated thermogenesis – Journal of Biological Chemistry, 2022

  • 🏥 Age-dependent sex differences in NAFLD in TSOD and db/db mice – PLOS ONE, 2022

  • 🐭 Dietary oleamide attenuates obesity in caged mice – Bioscience, Biotechnology, and Biochemistry, 2022

  • 🌿 Curcumin targets GPR55 receptor – npj Science of Food, 2022

  • 💪 Oleamide rescues muscle atrophy in small-caged mice – British Journal of Nutrition, 2021

🧾 Conclusion:

Dr. Naoki Harada demonstrates a clear trajectory of research excellence, grounded in scientific rigor and driven by impactful biomedical questions. His ability to identify molecular mechanisms (e.g., REDD2’s role in β-cell dysfunction) and propose therapeutic directions sets him apart as a leading academic in metabolic disease research. His publication record, industry collaborations, and professional memberships underscore a mature and influential academic career.

Carlos Cruchaga | Neuronal Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Carlos Cruchaga | Neuronal Cell Biology | Best Researcher Award

Dr. Carlos Cruchaga, Washington Univeristy, United States

Dr. Carlos Cruchaga is a tenured Professor at Washington University School of Medicine, with joint appointments in Psychiatry, Genetics, and Neurology. He is the Director of the NeuroGenomics and Informatics Center and leads multiple high-impact cores including the Knight ADRC, DIAN Genetics Core, and Biorepository Core for initiatives like the Dystonia Coalition and Aging Adult Brain Connectome. Internationally recognized for his pioneering work in neurodegenerative diseases, Dr. Cruchaga specializes in integrating multi-omic datasets to identify novel genetic and molecular mechanisms underlying Alzheimer’s disease and other neurological disorders. He has authored over 340 peer-reviewed publications and continues to lead major NIH-funded projects. With a strong commitment to translational research, he also contributes to tool development for omics data analysis. His work consistently bridges the gap between basic research and clinical application, making him a deserving candidate for the Best Researcher Award.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  • Leadership: Director of NeuroGenomics and Informatics Center; leads major genetics cores (Knight ADRC, DIAN, Dystonia Coalition, AABC).

  • Research Impact: Over 346 peer-reviewed publications with significant contributions in Alzheimer’s Disease (AD), neurodegeneration, multi-omics, and genetic epidemiology.

  • Translational Focus: Discoveries such as rare variants in AD-related genes (APP, PSEN1, PSEN2, PLD3, TREM2) and biomarker identification have major clinical implications.

  • Global Collaborations: Works with international research consortia including ADNI, GERAD, and Alzheimer’s Research UK, showing both scientific influence and collaboration.

  • Recognition: Invited speaker at high-level conferences; selected for the prestigious Spanish “Excellence Campus 2005”.

  • Innovation: Pioneered multi-omic and bioinformatic pipelines for biomarker discovery.

⚠️ Areas for Improvement:

  • Public Outreach: While academically exceptional, public or patient-facing outreach or science communication isn’t highlighted.

  • Diversity Initiatives: Potential to expand into mentorship programs or initiatives focused on increasing diversity in genomics.

  • Commercialization: There is room to emphasize translational science through startups, patents, or technology transfer.

🎓 Education:

Dr. Cruchaga earned his undergraduate degree in Biochemistry from the University of Navarra, Pamplona, Spain (1996–2000). He continued his graduate studies at the same institution, obtaining an MA (2000–2002) followed by a PhD in Biochemistry and Molecular Biology in 2005. His doctoral research, awarded Summa Cum Laude, focused on molecular mechanisms and biomarkers associated with neurodegenerative diseases. Dr. Cruchaga was selected among Spain’s top 18 PhD students to present his research at the “Excellence Campus 2005,” hosted by the Spanish Government and attended by Nobel Laureates. His training included foundational roles as a student and teaching assistant in the Department of Biochemistry and Molecular Biology, setting the stage for a career deeply rooted in research excellence and academic mentorship. This strong academic background has been instrumental in shaping his translational approach to complex neurological conditions like Alzheimer’s and dystonia.

💼 Experience:

Dr. Cruchaga has amassed extensive experience across academic, administrative, and research leadership roles. Since 2019, he has served as a Professor in Psychiatry, Genetics, and Neurology at Washington University. He is also the current Director of the NeuroGenomics and Informatics Center (since 2018), where he supervises multi-disciplinary teams and oversees high-throughput genomics operations. He leads cores in major initiatives such as the Knight Alzheimer’s Disease Research Center (ADRC), DIAN (Dominantly Inherited Alzheimer Network), and the Dystonia Coalition. Earlier roles include serving on the Alzheimer’s Association International Conference Scientific Program Committee (2014–2017), where he curated session topics, evaluated hundreds of abstracts, and chaired sessions. His international collaborations span omics, imaging, and computational biology, making him a leader in neurogenomics. These diverse roles have allowed Dr. Cruchaga to influence both scientific innovation and strategic planning within global neuroscience research initiatives.

🏅 Honors and Awards:

Dr. Cruchaga’s excellence has been recognized through numerous awards and invitations. In 2005, he was chosen for “Excellence Campus 2005,” a prestigious event featuring the top Spanish PhD students alongside Nobel Prize winners. He has received multiple invitations for keynote lectures and seminars at institutions across Europe and the U.S., including the University of the Basque Country, the Center for Applied Medical Research in Pamplona, and Washington University. He was a finalist for the O’Leary Award for Research in Neuroscience in 2009. His service as a Scientific Program Committee Member for the Alzheimer’s Association International Conference further underscores his leadership in the field. These accolades not only celebrate his scientific contributions but also affirm his status as a thought leader in neurodegenerative disease research. His peer-reviewed work has appeared in top-tier journals like Nature, Neuron, and Acta Neuropathologica.

🔬 Research Focus:

Dr. Cruchaga’s research centers on understanding the molecular and genetic underpinnings of neurodegenerative diseases, particularly Alzheimer’s disease, using integrative multi-omics approaches. His lab specializes in analyzing genomic, transcriptomic, proteomic, and metabolomic data from human biospecimens to uncover biomarkers, risk variants, and causal pathways. He has led groundbreaking studies identifying rare coding variants in genes like TREM2, PLD3, and APP, linking them to Alzheimer’s pathology. He applies advanced computational tools and machine learning to interpret high-dimensional data and translate findings into diagnostic and therapeutic strategies. As director of several national consortia cores (e.g., Knight ADRC, DIAN), he facilitates data-sharing and harmonization across global cohorts. His work also explores the genetic architecture of disorders like dystonia and peripheral neuropathy. The long-term goal of his research is to bridge omics data with clinical outcomes to enable personalized medicine in neurology.

📚 Publications Top Notes:

  1. 🧠 Rare variants in APP, PSEN1 and PSEN2 increase AD risk in late-onset families – PLoS One (2012)

  2. 🧬 GWAS of CSF tau levels reveals novel AD risk variants – Neuron (2013)

  3. 🧠 Rare coding variants in PLD3 gene confer AD risk – Nature (2014)

  4. 🧠 TREM2 coding variants increase AD risk – Human Molecular Genetics (2014)

  5. 🧪 TREM2 variants linked to AD risk in African Americans – Mol Neurodegeneration (2015)

  6. 🧫 Higher CSF soluble TREM2 linked to AD mutation status – Acta Neuropathologica (2016)

  7. 🧪 Genetics of plasma analytes identifies novel biomarkers – Scientific Reports (2016)

  8. 🧬 Variants in Mendelian AD genes within ADSP – JAD (2025)

  9. 🧠 RFC1 AAGGG repeat expansions common in neuropathy – Preprint (2025)

  10. 🧪 Plasma proteomics uncovers novel AD biomarkers – Preprint (2025)

🧾 Conclusion:

Dr. Carlos Cruchaga exemplifies the highest standards of neuroscience and genomics research. His contributions have advanced the global understanding of Alzheimer’s disease, making him a top-tier candidate for the Best Researcher Award. His scientific leadership, prolific output, and translational success position him as a standout in the biomedical field.

Andrew Moran | Molecular Mechanisms Signaling | Best Researcher Award

Published on by Cell Biologist

Dr. Andrew Moran | Molecular Mechanisms Signaling | Best Researcher Award

Dr. Andrew Moran, University of Liverpool, United Kingdom

Dr. Andrew William Moran is a Research Associate at the University of Liverpool, UK, specializing in gastrointestinal physiology and nutrient sensing. With over two decades of research experience, his work has contributed significantly to understanding sugar sensing mechanisms and their implications for animal and human health. He holds dual honours in Biochemistry and Biological & Medicinal Chemistry from Keele University and a PhD in Biochemistry and Molecular Biology from the University of Liverpool. Dr. Moran has played key roles in industry-funded projects, notably with ADM International and Pancosma SA, contributing to patented innovations in sweetener technology. His cutting-edge research on intestinal transporters, gut hormones, and enteric nervous system function has led to over 20 peer-reviewed publications. His interdisciplinary collaborations span veterinary, nutritional, and molecular biology fields, making him a valuable asset in translational gastrointestinal science. His REF-submitted research underscores the real-world impact of his scientific contributions.

Publication Profile:  

Orcid

✅ Strengths for the Award:

  1. Robust Academic Foundation:

    • Dual honours in Biochemistry and Biological & Medicinal Chemistry (Keele University)

    • PhD in Biochemistry and Molecular Biology (University of Liverpool)

  2. Research Excellence & Impact:

    • Specializes in intestinal glucose transport, nutrient sensing, and gut-brain axis—key areas in both basic and applied science.

    • Authored 24 publications in Web of Science and 20 on PubMed, with an H-index of 15, indicating consistent impact.

  3. Translational & Applied Innovation:

    • Co-inventor on two international patents (WO2014033218A1 & WO2024121704A1) tied to sweetener additives—bridging lab discoveries with industrial application.

    • Projects funded by ADM International and Pancosma SA, highlighting industry trust.

  4. Collaborative Leadership:

    • Current research partnership with Dr. Ellen Roelfsema (Utrecht University) on metabolic syndrome in ponies—an example of cross-disciplinary collaboration.

    • Contribution to REF2021 and REF2024, showing national-level research evaluation engagement.

  5. Model Innovation:

    • Use of intestinal enteroids (mini-guts) in research, reflecting cutting-edge methodologies in gut physiology.

🧭 Areas for Improvement:

  • Editorial Leadership: There is no mention of editorial board roles or peer-review positions. Gaining visibility in editorial circles could amplify academic leadership.

  • Public Science Communication: While the research is strong, broader science communication (e.g., public outreach, open-access workshops, webinars) would further elevate his profile.

  • International Presence: While collaborations exist, a more visible presence through invited talks at global conferences or consortia could enhance reputation internationally.

🎓 Education:

Dr. Moran began his academic career with a BSc (Dual Honours) in Biochemistry and Biological & Medicinal Chemistry at Keele University from 1999 to 2002. He then pursued a PhD in Biochemistry and Molecular Biology at the University of Liverpool, completed in 2006. His doctoral work focused on molecular mechanisms governing intestinal function, laying the foundation for his future studies in gut nutrient sensing and transporter regulation. He has continually expanded his knowledge through postdoctoral training and research in gastrointestinal physiology. This includes both in vivo and in vitro experimental methodologies, ensuring a comprehensive approach to investigating intestinal health. His educational background supports a wide range of expertise—from fundamental biochemistry to applied animal nutrition and enteric neuroscience. His solid academic training is a core strength underpinning his contribution to translational and industry-focused research.

🧪 Experience:

Dr. Moran’s research experience spans over 20 years, with expertise in molecular physiology of the gastrointestinal system. Post-PhD, his early work investigated the regulation of intestinal SGLT1 transporters, combining cell-based and whole-organism experiments. From 2019 to 2022, he led a project exploring the adaptive responses of the gut to diet and development. His more recent work (2022–2024) focuses on sweetener additive development in swine, incorporating pig-specific intestinal enteroids. He is currently funded by ADM International and has previously collaborated with Pancosma SA, contributing to two international patents. Dr. Moran is also engaged in veterinary research, partnering with Utrecht University to study equine metabolic syndrome. He has served as both an academic researcher and a consultant on gut sensing and nutrient absorption. This blend of industry and academic experience strengthens his application for recognition as a leading researcher in the field of digestive sciences.

🔬 Research Focus:

Dr. Moran’s primary research interests lie in intestinal sugar and amino acid sensing, glucose transporter regulation, and the gut-brain axis. He uses both traditional and novel model systems, including intestinal enteroids (mini-guts), to explore physiological responses to dietary changes. His research particularly targets SGLT1 and GLUT2 transporters, sweet taste receptors (T1R2-T1R3), and enteroendocrine pathways, aiming to enhance feed efficiency and gut health in livestock. His focus on sweetener bioactivity has direct applications in agriculture and veterinary medicine. Additionally, Dr. Moran investigates how gut nutrient sensing influences systemic responses, including metabolic disorders like equine metabolic syndrome. By integrating biochemistry, molecular biology, and animal physiology, his research contributes to the development of functional feeds and dietary interventions. His work is highly translational, bridging laboratory research with field application, and has resulted in two patents, several international collaborations, and over 20 peer-reviewed journal articles, with research submitted for REF2021 and REF2024.

📚 Publications Top Notes:

  1. 📄 Luminal Sweet Sensing and Enteric Nervous System Participate in Regulation of Intestinal Glucose Transporter, GLUT2

  2. 📄 Nutrient sensing of gut luminal environment (Symposium: Proceedings of the Nutrition Society)

  3. 📄 Non-nutritive sweetener activation of the pig sweet taste receptor T1R2-T1R3 in vitro mirrors gut expression

  4. 📄 Toll-like receptor 9 in intestinal enteroendocrine cells induces cholecystokinin secretion

  5. 📄 High-Intensity Sweetener Enhances Intestinal SGLT1 and Improves Enteric Disorders in Rabbits

  6. 📄 Effect of Milk Replacer Composition on Intestinal Microbiota of Pre-ruminant Dairy Calves

  7. 📄 Host selectively shapes intestinal microbiota of carnivorous and omnivorous fish

  8. 📄 GLP-2 and Enteric Nervous System Regulate Intestinal Na+/Glucose Co-transport

  9. 📄 Deregulation of transcription factors in morbidly obese affects enteroendocrine cells

  10. 📄 Composition and diversity of pig gastrointestinal mucosa-associated microbiota under dietary influence

📝 Conclusion:

Dr. Andrew William Moran presents a strong and diverse research portfolio with a notable balance between fundamental science and industrial relevance. His innovation in nutrient sensing and gut physiology, coupled with active collaborations and patentable outputs, makes him an ideal candidate for the Best Researcher Award. With minor expansion in academic leadership and public engagement, Dr. Moran is poised to become a prominent figure in translational biosciences globally.

Mahedi Hasan | Plasma Medicine | Young Researcher Award

Published on by Cell Biologist

Mr. Mahedi Hasan | Plasma Medicine | Young Researcher Award

Mr. Mahedi Hasan, Shizuoka University, Japan

Mahedi Hasan is a promising Bangladeshi researcher with a strong academic and research foundation in genetic engineering and nanostructured optoelectronics. Currently pursuing his PhD at Shizuoka University, Japan, his work bridges plasma science with biomedical applications, focusing on cold atmospheric microplasma for drug delivery and cellular modulation. Previously, Mahedi completed his BS and MS in Genetic Engineering and Biotechnology from the University of Rajshahi with excellent academic distinction. He has published extensively in international peer-reviewed journals, collaborating with multinational research teams in Japan and Bangladesh. His passion lies in innovative, interdisciplinary approaches to solving complex biomedical problems, with a vision to improve targeted therapeutics. Mahedi has demonstrated remarkable dedication, from assisting in molecular biology labs to leading pioneering plasma-based biomedical research. With an emerging global presence and deep scientific curiosity, Mahedi Hasan is an ideal candidate for the Young Researcher Award.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Robust Academic Foundation

    • Strong academic performance in both undergraduate (CGPA 3.63) and postgraduate (CGPA 3.87) studies in Genetic Engineering & Biotechnology.

    • Currently pursuing a PhD in Optoelectronics and Nanostructure Science at a reputable Japanese institution (Shizuoka University), indicating a cross-disciplinary research approach.

  2. High-Impact Research Contributions

    • Authored 10+ peer-reviewed publications, several in Q1 journals, addressing cutting-edge topics such as cold atmospheric plasma (CAP), drug delivery, and cellular senescence.

    • Demonstrated innovation in plasma-assisted biomedical applications, including nose-to-brain delivery systems and BBB penetration strategies.

  3. International Collaboration and Experience

    • Collaborates with an international team across Bangladesh and Japan, engaging in complex projects with global relevance.

    • Ongoing research in Japan exposes him to high-end lab infrastructure and interdisciplinary training.

  4. Recognitions and Scholarships

    • Winner of the National Science and Technology (NST) Fellowship – 2019, a significant national-level endorsement of research potential.

    • Recipient of the Graduate Board Scholarship – 2019 for academic excellence.

  5. Consistent Research Focus

    • Maintains a clear research trajectory from plant plasma applications to nanotechnology and plasma-driven biomedical interventions, showcasing a deepening specialization.

🧩 Areas for Improvement:

  1. Independent Project Leadership

    • Most publications are collaborative; demonstrating leadership in principal investigator (PI)-style roles or initiating independent proposals would further establish his research autonomy.

  2. Wider Conference Participation

    • Engaging more frequently in international conferences and symposiums (oral/poster presentations) would enhance visibility and networking.

  3. Diversification of Funding Sources

    • Beyond national scholarships, pursuing international research fellowships (e.g., JSPS, DAAD, Marie Skłodowska-Curie) would show strategic initiative and grant-writing skills.

  4. Industrial/Clinical Relevance Expansion

    • Potential to link his plasma-based research with real-world medical or commercial applications through translational or industry-collaborative projects.

📘 Education:

Mahedi Hasan’s academic journey showcases consistent excellence. He is currently pursuing a Ph.D. in Optoelectronics and Nanostructure Science at Shizuoka University, Japan (2023–ongoing), where his research focuses on cold plasma-mediated drug delivery systems. He holds both Bachelor’s (2018) and Master’s (2019) degrees in Genetic Engineering and Biotechnology from the University of Rajshahi, Bangladesh. Despite delays in examination schedules, he graduated with distinction, securing a CGPA of 3.87/4.00 in MS and 3.63/4.00 in BSc. His academic records demonstrate a strong foundation in life sciences, biotechnology, and interdisciplinary research. Through his studies, he developed expertise in molecular biology, protein science, and advanced biomedical technologies. His transition into nanostructured optoelectronics further highlights his adaptability and commitment to advancing next-generation therapeutic technologies. Mahedi’s education reflects not only academic brilliance but also his progressive shift toward impactful, translational science.

🧪 Experience:

Mahedi Hasan has garnered substantial research experience across molecular biology and plasma-based therapeutics. He served as a Research Assistant at the

Apply now for the Plasma Medicine Research for Young Researcher Award—honoring early-career scientists advancing plasma technology in medicine. Open to researchers under 35. Submit your abstract and supporting documents today!

& Protein Science Lab in the Department of Genetic Engineering & Biotechnology, University of Rajshahi, from May 2019 to September 2023. His role included evaluating the effects of low-pressure dielectric barrier discharge (LPDBD) plasma on the growth, physiology, and nutritional properties of crops like wheat and maize. Prior to that, he completed a Research Internship in the same lab, where he explored the impact of LFGD plasma on agronomic and nutritional traits. His current Ph.D. research continues this trajectory, now exploring cold atmospheric microplasma for improved drug absorption across the blood-brain barrier and in cancer cells. Mahedi’s experience demonstrates a unique blend of plant and human model systems, bench-to-bedside translation, and strong interdisciplinary collaboration in both Bangladeshi and Japanese labs.

🏅 Awards and Honors:

Mahedi Hasan’s research potential has been recognized with several prestigious awards. In 2019, he received the National Science and Technology (NST) Fellowship from the Ministry of Science and Technology, Government of Bangladesh, a competitive award supporting emerging scientific talent. That same year, he was honored with the Graduate Board Scholarship by the University of Rajshahi, granted for his academic excellence during his Master’s studies. These accolades highlight his academic brilliance and commitment to impactful research. His continuous involvement in high-impact international collaborations and publications in reputable journals further solidify his reputation as a dedicated young scientist. As a Ph.D. candidate in Japan, he continues to contribute to frontier biomedical applications of microplasma technology. These honors, coupled with his impressive research output and global collaborations, make him an outstanding contender for any young researcher recognition.

🔬 Research Focus:

Mahedi Hasan’s research uniquely bridges biotechnology, plasma physics, and nanomedicine. His core focus is on the application of cold atmospheric microplasma in enhancing drug delivery, especially across complex barriers like the blood-brain barrier and into cancerous cells. His work explores microplasma-assisted nose-to-brain delivery systems, cellular senescence modulation, and targeted uptake of hydrophilic compounds. His research employs both cellular (in vitro) and animal (in vivo) models to study absorption efficiency, molecular interaction, and bioavailability of therapeutic agents. In his early work, he investigated plasma’s role in altering the physiology and nutritional value of crops. Now, through cutting-edge interdisciplinary collaborations at Shizuoka University, he is working at the frontier of plasma-assisted biomedical innovation, opening new doors for non-invasive drug delivery systems. This fusion of bioscience with physical sciences represents a novel, transformative approach, making his research both timely and globally significant.

📚 Publications Top Notes:

  1. 📄 Microplasma-Mediated Enhancement of FD-150 Uptake in HL-60 Cells

  2. 🧠 Absorption of FD-150 in Brain Endothelial Cells by Cold Atmospheric Microplasma

  3. 🧬 Exploring the Role of Microplasma for Controlling Cellular Senescence in Saccharomyces cerevisiae

  4. ⚡ Voltage Dependent Effect of Spiral Wound Plasma Discharge on DBC1.2 Cellular Integrity

  5. 🧪 Enhancing Galantamine Distribution in Rat Brain Using Microplasma-Assisted Nose-to-Brain Drug Delivery

  6. 🧫 Absorption of FD-150 into White Blood Cells by Microplasma

  7. 🚧 In Vitro Drug Delivery through the Blood–Brain Barrier Using Cold Atmospheric Plasma

  8. 🧼 Lipidomics of Microplasma-Irradiated Cells at Optimized Discharge Conditions for Absorption of High-Molecule Drug

  9. 🐍 Toxins Profiles and Histological Impact of Trimeresurus erythrurus Venom: In Vitro and In Vivo Study

  10. 🧯 Evaluation of Bungarus caeruleus Venom and Antivenom Efficacy Used in Bangladesh

📝 Conclusion:

Mahedi Hasan emerges as a highly promising young researcher with a multidisciplinary profile rooted in biotechnology, plasma science, and nanostructure-based drug delivery systems. His solid academic background, commendable publication record, and international research involvement make him a strong contender for the Young Researcher Award. While he could benefit from taking on greater research leadership and wider dissemination of his work, his achievements to date clearly indicate excellent potential for impactful scientific contributions in the coming years.